Biotech Profile
GeoVax – From HIV Vaccine Pioneer to Multi-Platform Developer Targeting 40 Million Immunocompromised Americans
Atlanta-based biotech GeoVax outlines how its multi-antigen MVA platform addresses critical gaps left by single-antigen vaccines, with three Phase 2 COVID-19 trials underway and a Phase 3 Mpox vaccine trial scheduled for H2 2026 Founded in 2001 from Emory University’s
5 September 2025